Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation

Journal Article · Wed Nov 01 00:00:00 EST 1989 · International Journal of Radiation Oncology, Biology and Physics; (USA)

DOI:https://doi.org/10.1016/0360-3016(89)90138-7· OSTI ID:5129908

Peretz, T; Nori, D; Hilaris, B; Manolatos, S; Linares, L; Harrison, L; Anderson, L L; Fuks, Z; Brennan, M F ^[1]

---

1. Memorial Sloan-Kettering Cancer Center, New York, NY (USA)

Between January 1 1974 and October 31 1987, 98 patients with biopsy proven unresectable adenocarcinoma of the pancreas were treated with I-125 implants during laparotomy. Presenting symptoms were pain, jaundice, and weight loss. All patients underwent laparotomy and surgical staging. Thirty patients had T1NoMo disease, 47 patients had T2-3NoMo disease, and 21 patients had significant regional lymph node involvement (T1-3N1Mo). The surgical procedure performed was biopsy only (16 patients), gastric bypass, biliary bypass, and partial or total pancreatectomy with incomplete resection. The total activity and the number of seeds used were determined from the Memorial Sloan Kettering Cancer Center (MSKCC) nomogram. Stereoshift localization X ray films were taken 3-6 days after operation. The mean activity, minimal peripheral dose (MPD), and volume of the implants were 35 mCi, 13,660 cGy, and 53 cm3, respectively. In addition, 27 patients received postoperative external irradiation and 27 patients received chemotherapy. Postoperative complications were observed in 19 patients. These included post-operative death (1 patient), biliary fistula (4), intraabdominal abscess (4), GI bleeding (3), gastric or small bowel obstruction (6), sepsis (5), and deep vein thrombophlebitis (4). Pain relief was obtained in 37/57 patients (65%) presenting with pain. A multivariate analysis showed that four factors significantly affected survival: T stage, N stage, administration of chemotherapy, and more than 30% reduction in the size of the implant on follow-up films. The median survival for the entire group was 7 months. A subgroup of patients with T1No stage disease who received chemotherapy survived 18.5 months. The indications for I-125 seed implantation in unresectable carcinoma of the pancreas are discussed.

• OSTI ID: 5129908
• Journal Information: International Journal of Radiation Oncology, Biology and Physics; (USA), Vol. 17:5; ISSN 0360-3016
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
CARCINOMAS
COMBINED THERAPY
PANCREAS
IODINE 125
MULTIVARIATE ANALYSIS
PATIENTS
RADIATION SOURCE IMPLANTS
SURGERY
SURVIVAL CURVES
BETA DECAY RADIOISOTOPES
BODY
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
ELECTRON CAPTURE RADIOISOTOPES
ENDOCRINE GLANDS
GLANDS
IMPLANTS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
MATHEMATICS
MEDICINE
NEOPLASMS
NUCLEI
ODD-EVEN NUCLEI
ORGANS
RADIATION SOURCES
RADIOISOTOPES
STATISTICS
THERAPY
550603* - Medicine- External Radiation in Therapy- (1980-)
550600 - Medicine